Skye Bioscience, Inc.

SKYESEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1516551

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	—	—	—	$2.9M	$1.9M
Operating Expenses	$30.2M	$34.7M	$18.3M	$7.8M	$6.3M
Operating Income (Loss)	-$30.2M	-$34.7M	-$18.3M	-$7.8M	-$6.3M
Interest Expense	$749.3K	$906.3K	$665.1K	$769.2K	$706.4K
Nonoperating Income (Expense)	$3.6M	-$2.9M	-$1.2M	-$672.4K	-$270.1K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$26.6M	-$37.6M	-$19.5M	-$8.5M	-$6.6M
Income Tax Expense (Benefit)	$10.1K	$3.6K	$6.7K	$2.1K	$1.6K
Net Income (Loss) Attributable to Parent	-$26.6M	-$37.6M	-$19.5M	-$8.5M	-$6.6M
Earnings Per Share, Basic	-$0.73	-$5.37	-$8.77	-$0.02	-$0.03
Earnings Per Share, Diluted	-$0.73	-$5.37	-$8.77	-$0.02	-$0.03

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$72.8M	$11.9M	$9.1M	$9.9M	$2.7M
Assets, Current	$70.8M	$11.7M	$8.9M	$9.6M	$2.7M
Cash and Cash Equivalents, at Carrying Value	$68.4M	$1.3M	—	—	—
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Liabilities	$4.6M	$14.1M	$12.1M	$4.0M	$2.2M
Liabilities, Current	$4.3M	$13.9M	$12.1M	$3.9M	$787.2K
Accounts Payable, Current	$569.3K	—	—	$897.9K	$364.3K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$25.2M	-$14.0M	-$12.7M	-$6.5M	-$6.1M
Net Cash Provided by (Used in) Investing Activities	-$245.6K	$6.6M	$5.2M	-$90.9K	-$7.2K
Net Cash Provided by (Used in) Financing Activities	$83.6M	$16.4M	-$208.8K	$13.1M	$6.7M
Payments to Acquire Property, Plant, and Equipment	$1.6M	$12.6K	$28.1K	$90.9K	$7.2K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)